Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03111901
Title Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Acronym UVA-AM-002
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors William Grosh, MD
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.